Orange Book product · Generic (ANDA)
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
At a glance
Jul 02, 2018
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 02, 2018
8 yr 1 mo ago
Today
Pharmaceutical detail
Active ingredient
CASPOFUNGIN ACETATE
Strength
50MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
Not listed
Application
ANDA 205923
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CASPOFUNGIN ACETATE
- 2016CASPOFUNGIN ACETATEBrand (NDA)
NDA 206110 · FRESENIUS KABI USA
- 2001CANCIDASBrand (NDA)
NDA 021227 · MERCK
- 2025CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 216506 · HANGZHOU ZHONGMEI
- 2021CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 211263 · AREVA PHARMS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 209489 · CIPLA
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 200833 · HENGRUI PHARMA
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207092 · GLAND
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207650 · PHARMOBEDIENT
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
